Corpus ID: 8414274

Analysis of "early" thymidine/inosine protection as an adjunct to methotrexate therapy.

@article{Eleff1985AnalysisO,
  title={Analysis of "early" thymidine/inosine protection as an adjunct to methotrexate therapy.},
  author={M G Eleff and Pat Franks and Galen L. Wampler and Jerry M. Collins and I. David Goldman},
  journal={Cancer treatment reports},
  year={1985},
  volume={69 7-8},
  pages={
          867-74
        }
}
The feasibility of "early" thymidine and inosine protection of methotrexate (MTX) toxicity is evaluated in this paper. This approach is based on the proposition that the most vulnerable period for susceptible host cells to MTX toxicity is an interval following a pulse of MTX when the MTX monoglutamate level is high. In contrast, tumor cells that accumulate active MTX polyglutamyl derivatives are exposed to the cytotoxic effects of MTX, not only when the monoglutamate levels are high, but also… Expand
5 Citations
Biochemical Rationale for Selectivity in the Modulation of Methotrexate Activity During Leucovorin Rescue or Early Nucleoside Protection
TLDR
No clear biochemical rationale has been defined that could provide a basis for an inherent selectivity in the use of thymidine with methotrexate as an antineoplastic regimen. Expand
Clinical use of thymidine as a rescue agent from methotrexate toxicity
TLDR
Thymidine has been available for clinical research as a rescue agent since 1978 and has been used in conjunction with leucovorin and alkaline hydration to protect patients with acute renal dysfunction from life-threatening methotrexate toxicity. Expand
Rescue after intermediate and high-dose methotrexate: background, rationale, and current practice.
TLDR
Clinical and laboratory findings indicate that while the early start of FA administration is unnecessary for protecting normal cells, it is potentially dangerous in terms of reduction of the antitumor effect of methotrexate. Expand
Discovery of circulating DMARD response biomarkers in rheumatoid arthritis
TLDR
It is established that the ratio between relative numbers of CD169+ monocytes and CD43+ Tregs, two key cells in inflammation, are positively associated with disease activity in RA patients. Expand
Clinical and Laboratory Associations with Methotrexate Metabolism Gene Polymorphisms in Rheumatoid Arthritis
TLDR
Genotyping strategies could help prioritise treatments to RA patients most likely to gain clinical benefit whilst minimizing toxicity, as well as investigate the relationship between DMARD-metabolising gene variants and plasma metabolite levels in RA patients. Expand